Live Breaking News & Updates on Lung Cancer Conference

Stay updated with breaking news from Lung cancer conference. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

First-Line Anlotinib Plus Etoposide and Carboplatin Improves PFS in ES-SCLC

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC. ....

Republic Of Singapore , European Lung Cancer Congress , Lung Cancer , Lung Cancer Conference ,

Dr Curran on Developing Strategies for Stage III NSCLC Management

Wally Curran, MD, discusses current and developing treatment strategies for patients with stage III unresectable non–small cell lung cancer. ....

Wally Curran , Piedmont Oncology Institute , Lung Cancer Conference , Patients With Stage Iii Unresectable Non Small Cell Lung Cancer , Piedmont Oncology Institute ,

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors. ....

Department Of Hematology , Emory University School Of Medicine , Thoracic Medical Oncology Program , Ticiana Leal , Medical Oncology , Emory University School , Lung Cancer Conference , Per Winter Lung Cancer Conference , Dll3 Targeted Agents , Patients With Small Cell Lung Cancer , Neuroendocrine Tumors ,

FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

The FDA has granted a fast track designation to BI 764532 for use as a therapeutic option in patients with advanced or metastatic DLL3-expressing large-cell neuroendocrine carcinoma of the lung who experienced disease progression after treatment with 1 or more lines of therapy, including platinum-based chemotherapy. ....

Republic Of Singapore , Oxford Biotherapeutics , Christian Rohlff , Martin Wermke , Boehringer Ingelheim , University Hospital Carl Gustav Carus , Early Clinical Trial Unit , National Center , Tumor Diseases Dresden , Lung Cancer , G Liket Cell , Lung Cancer Conference ,

Emerging TROP-2 Directed ADCs Show Promise in Advanced NSCLC

Benjamin Philip Levy, MD, discusses the current landscape of emerging antibody-drug conjugates (ADCs) and their early activity in advanced lung cancer, the potential utility of oncogene-directed ADCs for patients with driver mutations, and more. ....

Johns Hopkins University , United States , New York , Johns Hopkins University School Of Medicine , Benjamin Philip Levy , Johns Hopkins University School , Medical Oncology , Johns Hopkins Sidney Kimmel Cancer Center , Sibley Memorial Hospital , Annual New York Lung Cancers Symposium , International Associated , Lung Cancer , World Lung Cancer , Lung Cancer Conference , Antibody Drug Conjugates , Datopotamab Deruxtecan , Sacituzumab Govitecan , T Dxd ,